In The News

In FDLI Update, Attorneys Examine Recent Trends for FDCA Injunctions

Practices: FDA Regulatory, Life Sciences, Litigation, Health Care, Digital Health

The U.S. Food & Drug Administration views injunctions as important both for correcting particular violations and for serving as a deterrent to incentivize other industry participants to comply voluntarily with FDA requirements.

A Food & Drug Law Institute Update Magazine article describes the historical use of and current policy standards for pursuing the Federal Food, Drug and Cosmetic Act injunctions, summarizes the typical characteristics and provisions of a consent decree of permanent injunction, and analyzes FDCA injunction cases filed since 2013 to identify key trends and takeaways for FDA-regulated entities.

The article was authored by life sciences regulatory & compliance counsel Beth Weinman and associates Joshua Oyster (both of Washington, D.C.) and Jessica Band (San Francisco). Josh and Jessica are hosting an “Author Happy Hour” sponsored by the Food and Drug Law Institute to discuss their article on January 12, 2021. You may register for the eventhere.

Cookie Settings